Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Interest & Investment Income for 14 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 14.29% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $24.2 million (down 31.29% YoY), while the FY2025 annual figure was $25.0 million, down 32.43% from the prior year.
• Interest & Investment Income slipped to $6.0 million in Q1 2026 per RARE's latest filing, from $6.5 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $10.7 million in Q3 2024 and bottomed at $494000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $6.2 million across 5 years, with a median of $6.2 million in 2022.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 1308.64% — and 2025, when it tumbled 45.36%.
• Ultragenyx Pharmaceutical's Interest & Investment Income stood at $6.2 million in 2022, then soared by 43.03% to $8.9 million in 2023, then gained by 13.3% to $10.0 million in 2024, then plunged by 35.17% to $6.5 million in 2025, then decreased by 7.86% to $6.0 million in 2026.
• Business Quant data shows RARE's Interest & Investment Income at $6.0 million in Q1 2026, $6.5 million in Q4 2025, and $5.9 million in Q3 2025.